Survival improvement and prognostic factors in recent management of extrahepatic cholangiocarcinoma: A single-center study

Cholangiocarcinoma was considered as a dismal disease with very poor prognosis until recently. Cholangiocarcinoma is increasingly found due to increased life expectancy. Although surgical and medical management were advanced recently, data on the prognosis, especially extrahepatic cholangiocarcinoma...

Full description

Saved in:
Bibliographic Details
Published in:Hepatobiliary & pancreatic diseases international 2020-04, Vol.19 (2), p.153-156
Main Authors: Choe, Jung Wan, Kim, Hyo Jung, Kim, Jae Seon
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bile Duct Neoplasms - pathology
Bile Duct Neoplasms - therapy
Bile Ducts, Extrahepatic - surgery
Chemotherapy, Adjuvant
Cholangiocarcinoma
Cholangiocarcinoma - secondary
Cholangiocarcinoma - therapy
Cisplatin - administration & dosage
Comorbidity
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Female
Humans
Male
Middle Aged
Palliative Care
Prognosis
Retrospective Studies
Risk Factors
Survival
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cholangiocarcinoma was considered as a dismal disease with very poor prognosis until recently. Cholangiocarcinoma is increasingly found due to increased life expectancy. Although surgical and medical management were advanced recently, data on the prognosis, especially extrahepatic cholangiocarcinoma (ECC), were limited. This study aimed to identify clinicopathologic features and prognosis of patients with ECC. Patients followed up and diagnosed with ECC between January 2014 and December 2016 at a tertiary hospital were included, whereas those with intrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary cancer were excluded. A total of 83 patients were followed after the treatment (49 men and 34 women; median age 73.3 years). Cancer location was classified as distal common bile duct (25 patients), proximal common bile duct (24 patients), common hepatic duct (20 patients), and hilar (14 patients). About 14.5% of patients had history of another malignant neoplasm, and 24.1% patients had chronic illness. Surgical resection was performed in 54 patients (65%) and dysplasia was combined in 63% (34/54). Adjuvant chemotherapy was performed in 54% (29/54), but only 7 underwent palliative chemotherapy in 29 nonsurgical patients. The median overall survival in all patients was 30.9 months. In analyzing the treatment modality, median survival of adjuvant chemotherapy, surgery only, palliative chemotherapy, and supportive care groups were 42.9, 30.9, 12.0, and 8.9 months, respectively (P 
ISSN:1499-3872
DOI:10.1016/j.hbpd.2019.12.011